Clinical trial of 13-cis-retinoic acid for children with high-risk neuroblastoma

Clinical trial of 13-cis-retinoic acid for children with high-risk neuroblastoma - Clinical trial of 13-cis-retinoic acid for children with high-risk neuroblastoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013672

Enrollment

Registered

2014-05-01

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk neuroblastoma

Interventions

Roaccutane 100mg/m2 internal use for 6 months. Total amount of Roaccutane is 18000mg/m2.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: High-risk neuroblastoma

Exclusion criteria

Exclusion criteria: The patient whom the doctor judged to be unsuitable for this clinical trial

Design outcomes

Primary

Measure	Time frame
The long-term outcome of high-risk neuroblastoma patients	—

Secondary

Measure	Time frame
Recurrence of neuroblastoma The safety of 13-cis RA	—

Countries

Japan

Contacts

Public ContactHideaki Maeba

Kanazawa university Pediatrics

pedialib@med.kanazawa-u.ac.jp076-265-2313

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026